Ace Therapeutics, a contract research organization specializing in translational blood disorder research, announced on June 26, 2026, the launch of a comprehensive suite of integrated preclinical hematology CRO services. This expansion aims to support the development of novel therapeutics for a wide range of hematologic diseases, which include complex pathologies affecting red blood cells, white blood cells, platelets, bone marrow, and lymphatic systems. These conditions encompass inherited anemias, autoimmune blood disorders, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders.
Traditional preclinical research in hematology often faces challenges with model translatability and fragmented study execution, creating bottlenecks for biotech and pharmaceutical companies developing gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments. Ace Therapeutics addresses these pain points through vertically integrated services that unify in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics under a fully integrated scientific framework.
The company offers a robust collection of in vivo hematologic disease models built across multiple preclinical species, including mice, rats, dogs, and non-human primates. The categorized model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines. These models are designed to improve translatability and accelerate the regulatory advancement of novel therapeutics.
In addition to in vivo models, the preclinical hematology CRO services include cutting-edge in vitro modeling platforms. These include biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays using primary human CD34+ hematopoietic stem and progenitor cells sourced from bone marrow, cord blood, and mobilized peripheral blood.
The services extend across the full drug development lifecycle, from target identification and CRISPR-based target validation to specialized PK/PD profiling tailored to blood disorder therapeutics. Hematology-focused safety pharmacology and toxicology assessments help evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues, including the spleen and bone marrow. Specialized technical support is offered for all therapeutic modalities, ranging from small-molecule iron chelators and JAK inhibitors to monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients seeking customized research programs can collaborate with Ace Therapeutics to design tailored study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions.
This launch underscores the growing need for specialized CRO services in hematology, as the pipeline of blood disorder therapeutics continues to expand. By offering a comprehensive, integrated approach, Ace Therapeutics aims to reduce development timelines and improve the success rate of novel treatments for patients with hematologic diseases.
